June 5, 2019

Enzyvant today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for RVT-802, a novel investigational tissue-based regenerative therapy designed to treat pediatric congenital athymia, and granted Priority Review.

April 3, 2019

Enzyvant today announced that its investigational regenerative treatment (RVT-802) in late-stage development for congenital athymia will be featured during a platform presentation, at a symposium, and in a poster session at the Clinical Immunology Society (CIS) 2019.

March 21, 2019

The FDA has granted Rare Pediatric Disease and Fast Track designations for RVT-801, an investigational enzyme replacement therapy.

February 21, 2019

Rachelle is a proven leader and operator with deep experience bringing valued medicines to market in complex, fast-moving business environments,

February 4, 2019

Abstracts highlighting the development of its investigational RVT-801 program and the natural history of Acid ceramidase deficiency will be presented in Orlando, Florida, by Enzyvant and its collaborators at the 2019 WORLDSymposium™

Enzyvant today announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development, further building the capabilities of the company.

July 28, 2018

Enzyvant announced today the appointments of Andrew Dawson to head human resources and Alex Tracy, PhD to lead development and manufacturing, enhancing the overall capabilities of the company

July 19, 2018

Enzyvant today announced that it has formed a collaboration with PerkinElmer Genomics, a global genomic testing company, to screen for mutations in the ASAH1 gene.

July 9, 2018

Enzyvant, announced today that it has initiated its rolling submission of a Biologics License Application (BLA) for RVT-802 to the U.S. Food and Drug Administration (FDA).

July 5, 2018

Enzyvant today announced that it has formed a partnership with Visikol, a contract research organization focused on digital pathology and drug discovery.

June 4, 2018

Enzyvant today announced the appointments of Alan Kimura, MD, PhD as Chief Medical Officer and Tamara Joseph, JD, LLM as General Counsel.

February 28, 2018

Re:GenerationHope raises awareness and funds for the Pediatric congenital athymia community

October 16, 2017

Global study aims to define the natural course of Acid ceramidase deficiency

September 5, 2017

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802

September 5-8, 2017

Enzyvant will present two posters and an oral presentation at the WORLD Symposium in San Diego

April 17, 2017

Enzyvant receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for RVT-802

February 28, 2017

Enzyvant is participating in rare disease day! Click below for a list of local events

February 15, 2017

Enzyvant will be presenting two posters at the ICIEM conference in Rio de Janeiro, Brazil

January 9-11, 2017

Come meet us at “Rare in the Square” in Union Square, San Francisco

January 6, 2017

Enzyvant to develop a novel biologic therapy for the treatment of immunodeficiency in Pediatric congenital athymia

November 1, 2016

Enzyvant has announced the appointment of Dr. Alvin Shih as Chief Executive Officer

July 12, 2016

Roivant Sciences Ltd. and Plexcera Therapeutics LLC have announced the formation of Enzyvant Ltd.